Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Yozgat A. K. , LEBLEBİSATAN G. , AKBAYRAM S., Ozel S. C. , Karakas Z., ERDURAN E., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.37, ss.139-144, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.